This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson’s disease


Li, Wei, Zhao, Jian-Hua, Sun, Sheng-Gang, Zhang, Jie-Wen, Suo, Ai-Qin, Ma, Ming-Ming


Zhonghua Yi Xue Za Zhi, Volume: 91, No.: 5, Pages.: 301-303

Year of Publication



Objective: To study the effects of memantine on cognitive and motor impairment in patients with Parkinson’s disease (PD).; Methods: A total of 55 PD patients complicated by varying degrees of cognitive impairment were randomly divided into two groups. The patients of experimental group (n = 28) received memantine (20 mg/d) while those in the control group (n = 27) conventional antiparkinsonian drug therapy alone. The cognitive and motor evaluations were assessed at pre-treatment and 12, 24 weeks post-treatment by clinical assessment, rating scales and neuropsychological tests.; Results: At week 24 the patients in the memantine group had better MMSE (22.8 ± 1.8), ADAS-cog (18.6 ± 2.3), and UPDRS-III (34.6 ± 4.2) scales scores than those taking placebo MMSE (18.5 ± 1.7), ADAS-cog (21.9 ± 2.4), and UPDRS-III (41.2 ± 4.0). Patients treated with memantine had better improvement on the MMSE (P < 0.05), ADAS-cog (P < 0.05), and UPDRS-III (P < 0.05) scales compared with the control group by the end of study week 24.; Conclusion: Memantine may improve the cognitive and motor impairments of PD. And it is both safe and well-tolerated.;


adverse effects, aged, antiparkinson agents, antiparkinsonian, cognition disorders, drug, drug therapy, female, function, humans, male, memantine, middle aged, motor, parkinson disease, therapeutic use, therapy, treatment outcome

Countries of Study


Types of Dementia

Parkinson’s Dementia

Types of Study

Randomised Controlled Trial

Type of Outcomes

Cognition, Other

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime, Other